Rituximab

This fact sheet has been designed by Lung Foundation Australia to help people living with pulmonary fibrosis to understand more about the immunosuppressant medication, Rituximab (MabThera, Ruxience, Riximyo, Truxima).

Rituximab is used to reduce inflammation in the lungs, which can lead to fibrosis or scarring.
Before starting rituximab, it is important to inform your doctor about any allergies, current medications, and existing health conditions, especially infections or heart disease. Rituximab is not recommended for pregnant or breastfeeding women, so it is important to consult your doctor if you are or plan to become pregnant.

When starting rituximab, your doctor will determine the appropriate dosage. Rituximab is administered intravenously in a hospital setting, typically in two doses two weeks apart, with effects lasting six to nine months. Regular blood tests are necessary to monitor for side effects. Patients should also have regular check-ups with their healthcare provider to monitor lung function and overall health.

Patients should avoid live vaccines during treatment and consult their doctor before any vaccinations. It is also crucial to inform healthcare providers about rituximab use before any surgeries.

Rituximab can cause allergic reactions, particularly during the first infusion, and patients may receive additional medications to manage these reactions. Common side effects include digestive issues, muscle stiffness, and changes in taste. Serious side effects, such as severe skin reactions, breathing difficulties, and vision problems require immediate medical attention.

For detailed guidance on side effects and safety precautions, consult the Consumer Medicine Information leaflet and consult your healthcare provider. If you or someone you know is affected by pulmonary fibrosis, reaching out to the Lung Foundation Australia can provide valuable support and information. They are dedicated to helping patients navigate their journey and access the best possible care. For more information and support, individuals can contact the Lung Foundation Australia’s Information and Support Centre at 1800 654 301 or visit their website.